Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

On November 4, 2026 Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd (TSE: 4151) reported that eight abstracts related to ziftomenib, including four oral presentations and four posters, have been accepted for presentation at the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place December 12-15 in New Orleans. Kura and Kyowa Kirin are working together under a strategic collaboration and license agreement to develop and commercialize ziftomenib for the treatment of acute myeloid leukemia (AML) worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will include the first clinical results for ziftomenib in combination with the FLT3 inhibitors quizartinib and gilteritinib, longer-term frontline data for ziftomenib plus venetoclax and azacitidine, and an exploratory analysis of ziftomenib activity in molecularly defined AML subtypes beyond NPM1-mutated and KMT2A-rearranged disease.

"Our strategy is to establish ziftomenib as a preferred menin inhibitor for combination treatment, supported by clinical evidence across complementary therapeutic approaches," said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. "Our first clinical results with quizartinib and gilteritinib extend this strategy into FLT3 inhibitor combinations. Together with longer-term venetoclax and azacitidine results and studies of additional combinations, these presentations will help define ziftomenib’s potential as a backbone therapy from initial diagnosis through relapsed or refractory disease."

FLT3 mutations occur in nearly one third of patients with AML and approximately one half of those with an NPM1 mutation. This overlap makes NPM1/FLT3 co-mutated AML an important population for ziftomenib combination development.

Two oral presentations will report preliminary safety and clinical activity findings from ziftomenib combinations with FLT3 inhibitors:

KOMET-007: Ziftomenib plus quizartinib and intensive chemotherapy (7+3) in newly diagnosed NPM1/FLT3-ITD co-mutated AML
KOMET-008: Ziftomenib plus gilteritinib in relapsed or refractory (R/R) NPM1/FLT3 co-mutated AML
A poster presentation from KOMET-007 will provide longer-term follow-up on response durability, overall survival, and safety with ziftomenib plus venetoclax and azacitidine in patients with newly diagnosed NPM1-mutated AML who are ineligible for intensive chemotherapy. These findings support the ongoing global, randomized Phase 3 KOMET-017 registrational study evaluating this combination.

An exploratory analysis from KOMET-001 will describe clinical activity with ziftomenib monotherapy in patients with R/R AML without NPM1 mutations or KMT2A rearrangements whose disease harbors other genomic alterations associated with MEIS1 expression. The findings support further investigation of ziftomenib in additional molecularly defined AML populations.

Two additional oral presentations will feature ziftomenib. The first will report initial results from the PedAL Phase 1 ITCC-101/APAL2020K trial sponsored by Blood Cancer United and Princess Maxima Center evaluating ziftomenib with fludarabine and cytarabine in pediatric R/R acute leukemia. The second will present preclinical findings from additional subsets of menin-associated leukemias.

All eight abstracts related to ziftomenib, including those from investigator-sponsored trials, are available on the ASH (Free ASH Whitepaper) website.

Select 2026 ASH (Free ASH Whitepaper) Presentation Details

Abstract Title Abstract Number Presentation Details
Ziftomenib combined with gilteritinib for relapsed/refractoryNPM1andFLT3co-mutated acute myeloid leukemia (AML): First results from the KOMET-008 phase 1 study
Oral Presentation #66 Session 617
December 12
10:45 a.m. CST
Great Hall AD
Ziftomenib combined with intensive induction (7+3) and quizartinib for newly diagnosedNPM1-m andFLT3-ITD+ acute myeloid leukemia (AML): Preliminary results from KOMET-007
Oral Presentation #902 Session 617
December 14
3:00 p.m. CST
Great Hall BC
Ziftomenib combined with venetoclax/azacitidine in newly diagnosedNPM1-m acute myeloid leukemia (AML): Long-term results from KOMET-007 Poster Presentation #5192 Session 617
December 14
6:00-8:00 p.m. CST
Hall F
Clinical activity of ziftomenib extends beyondNPM1-mutated andKMT2A-rearranged acute myeloid leukemia (AML) intoMEIS1-associated genomic subtypes Poster Presentation #5190 Session 617
December 14
6:00-8:00 p.m. CST
Hall F
Ziftomenib combined with fludarabine and cytarabine in pediatric relapsed/refractory acute leukemia withKMT2Arearrangements,NUP98rearrangements, orNPM1mutations: First results of the phase 1 ITCC-101/APAL2020K trial (NCT06376162)
Oral Presentation #666
Session 616
December 13
5:45 p.m. CST
Hall B
SETBP1-mutant leukemias depend on MENIN-associated KMT2A chromatin complexes to maintain leukemogenic transcriptional programs Oral Presentation #101 Session 636
December 12
10:30 a.m. CST
Hall C

Conference Call and Webcast

Kura will host a webcast and conference call at 8:30 a.m. ET / 5:30 a.m. PT on December 15, 2026, featuring Kura management, Eunice Wang, M.D., Chief of Leukemia Service and Professor of Oncology at Roswell Park Comprehensive Cancer Center, and Amer Zeidan, M.B.B.S., M.H.S., Chief, Division of Hematologic Malignancies and Professor of Medicine at Yale School of Medicine. A live webcast and archived replay of the event will be available in the Investors section of Kura’s website at www.kuraoncology.com.

(Press release, Kura Oncology, NOV 4, 2026, View Source [SID1234674207])

Verismo Therapeutics to Present First-in-Human SynKIR™-310 KIR-CAR Clinical Data Showing Robust Antitumor Activity and Favorable Safety Profile in Oral Presentation at 68th ASH Annual Meeting

On November 4, 2026 Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, reported that clinical data from its ongoing Phase 1 CELESTIAL-301 trial (NCT06544265) of SynKIR-310 have been selected for an oral presentation at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 12-15, 2026, in New Orleans. The oral presentation will include updated clinical and pharmacokinetic/pharmacodynamic correlative data across SynKIR-310 dose cohorts 1 through 3 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) following at least two prior lines of therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the initial clinical readout, SynKIR-310 showed an 80% objective response rate (4 of 5 evaluable patients) and a 60% complete response rate across dose cohorts 1 and 2, and the median duration of response in patients with a complete response was not reached with one patient in continued complete response at the 12-month assessment. No cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade was reported in any patient treated at the first two dose levels, and no dose-limiting toxicities were observed. Three of the six treated patients received SynKIR-310 in the outpatient setting. Additional data will be presented at the ASH (Free ASH Whitepaper) 2026 oral session in December.

Verismo will also present two additional preclinical poster abstracts — a novel CD19/CD20 dual-targeted KIR-CAR and a head-to-head preclinical comparison of SynKIR-310 against single-chain CAR T designs. The dual-targeted construct (Yucel et al.) addresses antigen heterogeneity — a leading cause of relapse after conventional CD19 CAR T — and shows substantially reduced cytokine levels versus a single-chain benchmark. In the head-to-head comparison (Blair et al.), SynKIR-310 achieved deeper tumor control than single-chain CD19 CAR T designs with substantially lower cytokine production.

ASH 2026 — Clinical Oral Presentation

Title: First-in-human evaluation of SynKIR-310 employing a novel multi-chain KIR-based CAR demonstrates promising antitumor activity and no reported CRS or ICANS in patients with high-risk B-NHL
Presenter: Michael Tees, M.D., Colorado Blood Cancer Institute
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
Session Date and Time: Dec 13, 2026: 5:45 – 6:00 PM
Location: Ernest N. Morial Convention Center, New Orleans, Louisiana
Publication Number: 708
Full Abstract: View Source
Full Clinical Data Readout: Released at the time of presentation

ASH 2026 — Preclinical Poster Presentations

Poster 1 — Novel CD19/CD20 Dual-Targeted KIR-CAR
Title: CD19/20 dual targeted killer immunoglobulin-like receptor (KIR)-based CAR T eliminates antigen-heterogenous B cell lymphomas with reduced cytokine secretion and adaptable ex vivo or in vivo gene delivery
Presenter: Nora Yucel, Ph.D., Verismo Therapeutics
Session: 702. CAR-T Cell Therapies: Basic and Translational
Session Date and Time: Dec 14, 2026: 6 – 8 PM
Full Abstract: View Source

Poster 2 — SynKIR-310 vs. Single-Chain CAR T Preclinical Comparison
Title: CD19-targeted multi-chain killer immunoglobulin receptor (KIR)-based CAR T demonstrate an enhanced benefit-risk profile over single-chain CAR T
Presenter: Megan Blair, Ph.D., Verismo Therapeutics
Session: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational
Session Date and Time: Dec 14, 2026: 6 – 8 PM
Full Abstract: View Source

About the KIR-CAR Platform

The KIR-CAR platform is a multi-chain T cell therapy that has shown highly effective solid tumor treatment in otherwise CAR-resistant animal models with hard-to-treat tumors. Using NK cell-derived killer immunoglobulin-like receptor (KIR) and DAP12 to split the target binding and T cell activation signals provides a novel paired immune-receptor activation that is independent from CD3 signaling and does not require additional co-stimulation. KIR-CAR enables sustained cell receptor expression in T cells, and induces deeper, more durable tumor treatments. Together, this multi-chain cell signaling platform provides the potential to deliver effective patient treatments by minimizing the background activation and early T cell exhaustion observed in conventional single-chain CAR T therapy, with potential to treat patients with both solid and hematologic tumors. The KIR-CAR platform is adaptable to both ex vivo and in vivo delivery modalities.

(Press release, Verismo Therapeutics, NOV 4, 2026, View Source [SID1234674223])

Zelluna ASA: Third Quarter 2026 results

On November 4, 2026 Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, reported its results for the third quarter 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast scheduled for 5 November 2026 at 09:00 (CET). Link to webcast here.

Operational Highlights:

ZIMA-101 recruitment and dosing on track: Two of the three patients required at Dose Level 1 have now been successfully dosed, the second following the reporting period, with dosing of a third patient planned during Q4 2026 to complete this dose level. More than 30 patients have been screened for HLA-A2 and/or MAGE-A4 expression, with potential patients identified across all four target indications (ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer), demonstrating strong clinical site engagement and supporting continued recruitment momentum. Subject to completion of Dose Level 1 and a favourable subsequent safety review by the Independent Data Monitoring Committee (IDMC), Zelluna expects to begin and complete recruitment and dosing at Dose Level 2, representing a threefold increase in the administered cell dose compared with Dose Level 1, during Q1 through early Q2 2027.
No dose-limiting toxicities to date: ZI-MA4-1 has been well tolerated, with no dose-limiting toxicities reported in the two patients treated. On 17 August 2026, the Independent Data Monitoring Committee (IDMC) completed its planned safety review of the first patient and recommended continued recruitment at Dose Level 1.
Initial observations from patient samples: Preliminary blood measurements indicate cell kinetics consistent with expectations, alongside early changes in circulating pro-inflammatory immune markers following ZI-MA4-1 infusion. Clinical follow-up is ongoing, including further tumour imaging assessments and the collection and analysis of translational data from patients treated at Dose Level 1.
External clinical evidence supports TCR-NK therapeutic potential: Researchers at MD Anderson Cancer Center have reported a complete response in a heavily pre-treated multiple myeloma patient treated with an independently developed TCR-NK therapy. While generated in a different disease setting, this provides an encouraging external clinical demonstration that the TCR-NK approach can deliver anti-tumour activity in late-stage cancer patients.
Awarded NOK 15.6 million grant by the Research Council of Norway to further advance TCR-NK manufacturing: Following the reporting period, on 4 November 2026, Zelluna was awarded NOK 15.6 million in a grant by the Research Council of Norway. Funding will enable further manufacturing development and support Zelluna’s commercial strategy to make off-the-shelf TCR-NK cell therapies broadly accessible to patients with solid cancers. The award, which is subject to final contract negotiations, follows another grant awarded by the Research Council of Norway in June 2026 earlier this year to support the ZIMA-101 clinical programme.
Manufacturing process successfully executed at new CDMO: Following the reporting period, an initial manufacturing run was successfully completed at Zelluna’s new CDMO, an important step towards establishing manufacturing capabilities at the new facility and highlighting the potential transferability of Zelluna’s manufacturing process across sites, an important TCR-NK platform attribute supporting future scalability, manufacturing flexibility and cost efficiency. Analytical and functional characterisation of the resulting product is ongoing.
ZIMA-101 featured at leading international oncology conferences: Following the reporting period, the design of the ongoing ZIMA-101 Phase 1 study of ZI-MA4-1 was presented by Professor Fiona Thistlethwaite, Chief Investigator of the study at The Christie NHS Foundation Trust, at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid. A further poster presentation outlining the design of the study is scheduled for the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in November 2026.
Martin Welschof elected as new Board member: At an Extraordinary General Meeting held on 9 September 2026, Martin Welschof, CEO of BioInvent International AB, was elected as a new member of the Board, replacing Hans Ivar Robinson, who has stepped down from the Board. Martin Welschof has previously served as CEO of Affitech A/S and Opsona Therapeutics, holds a PhD in recombinant antibody technology and brings extensive international experience from executive leadership in clinical-stage and listed biotechnology companies.
Financial Highlights Q3 2026:

Total operating expenses: MNOK 28.8 in Q3 2026 and MNOK 69.2 YTD
Total loss: MNOK 29.0 in Q3 2026 and MNOK 69.0 YTD
Cash and cash equivalents: MNOK 60.4 as of 30 September 2026
Net negative cash flow from operations: MNOK 25.5 in Q3 2026
Financial runway: Into Q3 2027
Expected grants and tax credits: SkatteFUNN tax credits of MNOK 5.2 related to 2025 expected in Q4 2026, as well as the first payments under the MNOK 16 grant awarded by the Research Council of Norway in June 2026, with the remainder expected in 2027
Share issue to Inven2: On 4 August 2026, 446,752 new shares were issued at NOK 19.78 per share to settle EUR 791,666.70 under the option and license agreement with Inven2, triggered by the dosing of the first patient

"The third quarter marked Zelluna’s transition into a clinical-stage biotechnology company. We have now treated two patients in ZIMA-101, with no dose-limiting toxicities reported to date. Recruitment is on track, supported by strong engagement from our clinical sites and investigators driving continued progress towards completion of our first dose cohort and preparations for dose escalation.

Our immediate priority is to complete Dose Level 1 and progress towards a threefold higher dose, subject to independent safety review. This will be an important next step in exploring the therapeutic potential of TCR-NK for patients with solid tumours. We are also encouraged by emerging external clinical evidence, including the complete response reported with an independent TCR-NK therapy, demonstrating the potential of this approach to deliver meaningful anti-tumour activity in patients. With our differentiated platform, continued clinical execution, and sustained strategic interest in off-the-shelf cell therapies we believe Zelluna is well positioned to create value for patients and shareholders as clinical data builds" says CEO Namir Hassan.

"It is encouraging to see the progress in recruitment to the ZIMA-101 study, with patients being identified across several solid tumour indications. As an early-phase clinical trial evaluating a novel TCR-NK cell therapy, our initial focus is on establishing safety and progressing through dose escalation. We look forward to building on this early experience as the study advances." Prof. Fiona Thistlethwaite, Chief Investigator, ZIMA-101.

Outlook

Zelluna enters the final quarter of 2026 with encouraging initial clinical observations and recruitment and dosing progressing on track in the first-in-human ZIMA-101 study. The Company’s immediate priority is to complete Dose Level 1 and advance to Dose Level 2, where recruitment and dosing are expected to take place from Q1 through early Q2 2027, subject to completion of Dose Level 1 and a favourable subsequent IDMC safety review. The encouraging initial observations at the lowest planned dose level support continued dose escalation. Ongoing clinical and translational assessments of patients treated at Dose Level 1, together with data from higher dose levels, are expected to build a more comprehensive understanding of the safety and therapeutic potential of ZI-MA4-1. In parallel, Zelluna continues to strengthen its manufacturing capabilities and advance its TCR-NK pipeline, including the evaluation of AI-engineered TCR candidates targeting KKLC1. Zelluna’s cash position is expected to fund planned operations into the third quarter of 2027.

The quarterly report and presentation materials will be made publicly available on the Zelluna website at 07:00 CET on 5 November 2026. The Company will host a webcast on 5 November at 09:00 CET, and questions can be submitted during the event. The webcast recording will remain available on the Company’s website after the event.

(Press release, Zelluna Immunotherapy, NOV 4, 2026, View Source [SID1234674238])

Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026

On November 4, 2026 Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, reported that it will present an NXC-201 abstract at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) 68th Annual Meeting and Exposition to be held December 12-15, 2026, in New Orleans, LA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASH Oral Presentation Details:

Event 68th ASH (Free ASH Whitepaper) Annual Meeting and Exposition, New Orleans, LA
Title "45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in relapsed/refractory AL amyloidosis"
Presentation
Date/Time (Central Time)
Publication #826
Session Date: Monday, December 14, 2026
Session Name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis
Session Time: 10:30 AM -12:00 PM
Presentation Time: 11:15 AM
About AL Amyloidosis
Amyloid light-chain (AL) amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death.

AL amyloidosis is the most common form of amyloidosis according to the National Institutes of Health. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

(Press release, Immix Biopharma, NOV 4, 2026, View Source [SID1234674169])

Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance

On November 4, 2026 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, reported that the Company’s research examining a mechanism of resistance to CAR T-cell therapy and the potential of DNase I to reverse this process has been selected for oral presentation at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. The conference will take place December 12-15, 2026, in New Orleans, Louisiana, and virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will examine how extracellular chromatin released during CAR T-cell killing establishes a self-reinforcing resistance niche and how DNase I reverses this process. By investigating a resistance mechanism that arises during CAR T-cell killing itself, the research addresses a central challenge in the field: understanding how the response to tumor-cell destruction may create conditions that limit continued treatment activity.

The research will be featured in the session "Overcoming Resistance and Escape in CAR-T Cell Therapy," bringing this work to an audience focused on the biological barriers to effective CAR T-cell treatment and approaches to addressing them.

Oral Presentation Details

Title: Extracellular chromatin released during CAR T-cell killing establishes a self-reinforcing resistance niche reversed by DNase I
Presenter: Alexey Stepanov, Ph.D., Institute Investigator, Department of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, United States
Publication Number: 427
Session: 702. CAR-T Cell Therapies: Basic and Translational: Overcoming Resistance and Escape in CAR-T Cell Therapy
Date: Saturday, December 12, 2026
Presentation Time: 4:00-4:15 PM Central Time
Session Time: 4:00-5:30 PM Central Time
Location: Ernest N. Morial Convention Center, Room 343-345, New Orleans, Louisiana

The 68th ASH (Free ASH Whitepaper) Annual Meeting brings together the global hematology community to share advances in research and clinical care. For more information, please visit the conference website.

(Press release, Xenetic Biosciences, NOV 4, 2026, View Source [SID1234674185])